Caoileann H Murphy1, Ellen M Flanagan1, Giuseppe De Vito1,2, Davide Susta3,4, Kathleen A J Mitchelson1, Elena de Marco Castro1, Joan M G Senden5, Joy P B Goessens5, Agnieszka Mikłosz6, Adrian Chabowski6, Ricardo Segurado1,7, Clare A Corish1, Sinead N McCarthy8, Brendan Egan3, Luc J C van Loon5, Helen M Roche1,9. 1. School of Public Health, Physiotherapy and Sport Science, University College Dublin, Dublin, Ireland. 2. Department of Biomedical Sciences, University of Padua, Padua, Italy. 3. School of Health and Human Performance, Dublin City University, Dublin, Ireland. 4. Department of Normal Physiology, IM Sechenov First Moscow State Medical University, Moscow, Russia. 5. Department of Human Movement Sciences, Maastricht University, Maastricht, Netherlands. 6. Department of Physiology, Medical University of Bialystok, Bialystok, Poland. 7. UCD Centre for Support and Training in Analysis and Research (CSTAR), University College Dublin, Dublin, Ireland. 8. Teagasc Food Research Centre, Ashtown, Dublin, Ireland. 9. Institute for Global Food Security, Queen's University Belfast, Belfast, United Kingdom.
Abstract
BACKGROUND:Leucine-enriched protein (LEU-PRO) and long-chain (LC) n-3 (ω-3) PUFAs have each been proposed to improve muscle mass and function in older adults, whereas their combination may be more effective than either alone. OBJECTIVE: The impact of LEU-PRO supplementation alone and combined with LC n-3 PUFAs on appendicular lean mass, strength, physical performance and myofibrillar protein synthesis (MyoPS) was investigated in older adults at risk of sarcopenia. METHODS: This 24-wk, 3-arm parallel, randomized, double-blind, placebo-controlled trial was conducted in 107 men and women aged ≥65 y with low muscle mass and/or strength. Twice daily, participants consumed a supplement containing either LEU-PRO (3 g leucine, 10 g protein; n = 38), LEU-PRO plus LC n-3 PUFAs (0.8 g EPA, 1.1 g DHA; LEU-PRO+n-3; n = 38), or an isoenergetic control (CON; n = 31). Appendicular lean mass, handgrip strength, leg strength, physical performance, and circulatingmetabolic and renal function markers were measured pre-, mid-, and postintervention. Integrated rates of MyoPS were assessed in a subcohort (n = 28). RESULTS: Neither LEU-PRO nor LEU-PRO+n-3 supplementation affected appendicular lean mass, handgrip strength, knee extension strength, physical performance or MyoPS. However, isometric knee flexion peak torque (treatment effect: -7.1 Nm; 95% CI: -12.5, -1.8 Nm; P < 0.01) was lower postsupplementation in LEU-PRO+n-3 compared with CON. Serum triacylglycerol and total adiponectin concentrations were lower, and HOMA-IR was higher, in LEU-PRO+n-3 compared with CON postsupplementation (all P < 0.05). Estimated glomerular filtration rate was higher and cystatin c was lower in LEU-PRO and LEU-PRO+n-3 postsupplementation compared with CON (all P < 0.05). CONCLUSIONS: Contrary to our hypothesis, we did not observe a beneficial effect of LEU-PRO supplementation alone or combined with LC n-3 PUFA supplementation on appendicular lean mass, strength, physical performance or MyoPS in older adults at risk of sarcopenia. This trial was registered at clinicaltrials.gov as NCT03429491.
RCT Entities:
BACKGROUND:Leucine-enriched protein (LEU-PRO) and long-chain (LC) n-3 (ω-3) PUFAs have each been proposed to improve muscle mass and function in older adults, whereas their combination may be more effective than either alone. OBJECTIVE: The impact of LEU-PRO supplementation alone and combined with LC n-3 PUFAs on appendicular lean mass, strength, physical performance and myofibrillar protein synthesis (MyoPS) was investigated in older adults at risk of sarcopenia. METHODS: This 24-wk, 3-arm parallel, randomized, double-blind, placebo-controlled trial was conducted in 107 men and womenaged ≥65 y with low muscle mass and/or strength. Twice daily, participants consumed a supplement containing either LEU-PRO (3 g leucine, 10 g protein; n = 38), LEU-PRO plus LC n-3 PUFAs (0.8 g EPA, 1.1 g DHA; LEU-PRO+n-3; n = 38), or an isoenergetic control (CON; n = 31). Appendicular lean mass, handgrip strength, leg strength, physical performance, and circulating metabolic and renal function markers were measured pre-, mid-, and postintervention. Integrated rates of MyoPS were assessed in a subcohort (n = 28). RESULTS:Neither LEU-PRO nor LEU-PRO+n-3 supplementation affected appendicular lean mass, handgrip strength, knee extension strength, physical performance or MyoPS. However, isometric knee flexion peak torque (treatment effect: -7.1 Nm; 95% CI: -12.5, -1.8 Nm; P < 0.01) was lower postsupplementation in LEU-PRO+n-3 compared with CON. Serum triacylglycerol and total adiponectin concentrations were lower, and HOMA-IR was higher, in LEU-PRO+n-3 compared with CONpostsupplementation (all P < 0.05). Estimated glomerular filtration rate was higher and cystatin c was lower in LEU-PRO and LEU-PRO+n-3 postsupplementation compared with CON (all P < 0.05). CONCLUSIONS: Contrary to our hypothesis, we did not observe a beneficial effect of LEU-PRO supplementation alone or combined with LC n-3 PUFA supplementation on appendicular lean mass, strength, physical performance or MyoPS in older adults at risk of sarcopenia. This trial was registered at clinicaltrials.gov as NCT03429491.
Authors: Michaela C Devries; Christopher McGlory; Douglas R Bolster; Alison Kamil; Maike Rahn; Laura Harkness; Steven K Baker; Stuart M Phillips Journal: Am J Clin Nutr Date: 2018-02-01 Impact factor: 7.045
Authors: A C Tierney; J McMonagle; D I Shaw; H L Gulseth; O Helal; W H M Saris; J A Paniagua; I Gołąbek-Leszczyñska; C Defoort; C M Williams; B Karsltröm; B Vessby; A Dembinska-Kiec; J López-Miranda; E E Blaak; C A Drevon; M J Gibney; J A Lovegrove; H M Roche Journal: Int J Obes (Lond) Date: 2010-10-12 Impact factor: 5.095
Authors: Ian Janssen; Richard N Baumgartner; Robert Ross; Irwin H Rosenberg; Ronenn Roubenoff Journal: Am J Epidemiol Date: 2004-02-15 Impact factor: 4.897
Authors: Kun Zhu; Deborah A Kerr; Xingqiong Meng; Amanda Devine; Vicky Solah; Colin W Binns; Richard L Prince Journal: J Nutr Date: 2015-09-23 Impact factor: 4.798
Authors: Alfonso J Cruz-Jentoft; Gülistan Bahat; Jürgen Bauer; Yves Boirie; Olivier Bruyère; Tommy Cederholm; Cyrus Cooper; Francesco Landi; Yves Rolland; Avan Aihie Sayer; Stéphane M Schneider; Cornel C Sieber; Eva Topinkova; Maurits Vandewoude; Marjolein Visser; Mauro Zamboni Journal: Age Ageing Date: 2019-01-01 Impact factor: 10.668
Authors: Roma Krzymińska-Siemaszko; Natasza Czepulis; Marta Lewandowicz; Ewa Zasadzka; Aleksandra Suwalska; Janusz Witowski; Katarzyna Wieczorowska-Tobis Journal: Int J Environ Res Public Health Date: 2015-08-28 Impact factor: 3.390
Authors: Patricia S Rogeri; Rudyard Zanella; Gabriel L Martins; Matheus D A Garcia; Geovana Leite; Rebeca Lugaresi; Sandro O Gasparini; Giovana A Sperandio; Luis Henrique B Ferreira; Tacito P Souza-Junior; Antonio Herbert Lancha Journal: Nutrients Date: 2021-12-23 Impact factor: 5.717
Authors: Caoileann H Murphy; Claire Connolly; Ellen M Flanagan; Kathleen A J Mitchelson; Elena de Marco Castro; Brendan Egan; Lorraine Brennan; Helen M Roche Journal: J Cachexia Sarcopenia Muscle Date: 2022-02-21 Impact factor: 12.910